BackPacira BioSciences Overview

Pacira BioSciences Other Current Liabilities

Pacira BioSciences's other current liabilities is $94M.

Get informed when a big investor buys or sells

+ Follow
Other Current Liabilities
$94.20M
32.64% YoYΔ $23.18M vs prior year quarter

Peer trimmed avg / median

Loading

Pacira BioSciences Other Current Liabilities History

Loading

Pacira BioSciences vs. peers: Other Current Liabilities Comparison

Loading

Pacira BioSciences Other Current Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Pacira BioSciences (PCRX) FAQ

Pacira BioSciences (PCRX) currently reports a other current liabilities of $94M as of June 2026. That compares with $71M in the prior-year period — up 32.6% year over year. Use the charts on this page to explore Pacira BioSciences's other current liabilities history and peer comparisons.

Pacira BioSciences's other current liabilities increased from $71M to $94M — a 32.6% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Pacira BioSciences reported $94M in other current liabilities as of June 2026. That compares with $71M in the prior-year period — up 32.6% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current other current liabilities of $94M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Pacira BioSciences, and consider following PCRX for alerts when major investors trade the stock.

Pacira BioSciences is classified in the Healthcare sector. On other current liabilities, it currently shows $94M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing PCRX with unrelated industries.